Newsletter | October 22, 2020

10.22.20 -- Rituxan Biosimilars: Market & Clinical Considerations

Featured Editorial
Industry Insights
Is Your Biologics At Risk For Protein Aggregation? Part 2

The manufacture of sterile injectables is fraught with risk, especially when it comes to protein aggregation in biologics drugs. In the first part of this article, we discussed causes of protein aggregation and how you can stress test your drug. We now offer steps you can take to help prevent aggregation.

Raw Material Variability: The Need For Deeper Process Understanding

Principles and methods for biopharma development and manufacturing are well-established, but increased molecular diversity and a drive for higher productivity brings new challenges to process developers.

News Headlines